NASDAQ:PLUR Pluri 9/17/2025 Earnings Report $4.76 -0.15 (-2.96%) As of 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Pluri EPS ResultsActual EPSN/AConsensus EPS -$0.73Beat/MissN/AOne Year Ago EPSN/APluri Revenue ResultsActual RevenueN/AExpected Revenue$0.40 millionBeat/MissN/AYoY Revenue GrowthN/APluri Announcement DetailsQuarterDate9/17/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Pluri Earnings HeadlinesPluri Resolves Nasdaq Compliance Issue with New DirectorSeptember 12, 2025 | tipranks.comPluri Appoints Eitan Ajchenbaum to Board of DirectorsSeptember 11, 2025 | tipranks.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.September 16 at 2:00 AM | Brownstone Research (Ad)Pluri (PLUR) Projected to Post Earnings on WednesdaySeptember 10, 2025 | americanbankingnews.comPluri Inc. director not re-elected, Nasdaq compliance cure period grantedJuly 5, 2025 | investing.comAlliance Global Partners Initiates Coverage of Pluri (PLUR) with Buy RecommendationJune 2, 2025 | msn.comSee More Pluri Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pluri? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pluri and other key companies, straight to your email. Email Address About PluriPluri (NASDAQ:PLUR) (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting. Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies. Its PLX cell therapies have been evaluated in clinical studies targeting critical limb ischemia, hematopoietic support following radiation exposure and tissue repair in musculoskeletal injuries. The company has also received grant funding for programs addressing acute radiation syndrome and continues to explore additional indications in immune and inflammatory diseases. Headquartered in Haifa, Israel, Pluri operates a GMP-certified manufacturing facility capable of supporting commercial-scale production. The company’s global footprint extends to clinical trial sites and partnership agreements in the United States, Europe and the Asia-Pacific region. Pluri’s leadership team brings extensive expertise in regenerative medicine, cellular manufacturing and regulatory affairs as it works toward potential market authorization and broad clinical adoption of its cell therapy products.View Pluri ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Wall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a Winner Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
